May 14, 2014
Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)
A leading data-driven diagnostic solutions company helping answer critical clinical questions faced by physicians, researchers, and biopharmaceutical companies, with a primary focus in lung disease.
2970 Wilderness Place, Suite 100 Boulder, CO 80301
© Copyright 2021 Biodesix. All Rights Reserved.